Spectranetics Announces Executive Appointments to Further Enhance Compliance Programs

Spectranetics Corporation (Nasdaq:SPNC) today announced two executive appointments that reflect the Company’s commitment to high standards of regulatory compliance. Michael Handley, most recently Director, Global Regulatory Affairs and Compliance, has been promoted to the new position of Vice President, Global Regulatory Affairs and Compliance; and Elaine Messa has joined the Company as Interim Chief Compliance Officer, also a newly created, contracted position.

"The appointments of Mike and Elaine are another step in our ongoing commitment to continuous improvement in Spectranetics’ compliance programs,” said Emile Geisenheimer, Chairman, President and Chief Executive Officer.

Mr. Handley joined Spectranetics in April 2007 as Manager of Regulatory Affairs and was promoted to Director, Global Regulatory Affairs and Compliance in August 2007. Prior to joining Spectranetics, he served as Vice President, Regulatory Affairs for AccelaPure, a company providing pre-clinical and clinical services for biotechnology companies. Prior to that, Mr. Handley was Senior Principal at Pittiglio Rabin Todd & McGrath, a nationally recognized management consulting firm for the biopharmaceutical and medical device industries and a founder of Actus Partners, a consulting firm providing services in the areas of drug discovery, development and regulatory affairs. Mr. Handley graduated cum laude from Colorado State University with Bachelors of Science degrees in Molecular Biology, Physiology, and minors in Chemistry and Neurobiology.

Ms. Messa joins Spectranetics from Becker & Associates Consulting, Inc., where she serves as Director of the Medical Device Quality Systems and Compliance Practice Group, overseeing all medical device engagements related to compliance with the Food and Drug Administration (FDA) regulations. Prior to joining Becker & Associates Consulting, Ms. Messa held multiple roles during a 30 year career at the FDA, the last 16 of which were in management positions within FDA district offices. During her FDA tenure, she successfully established an industry grass roots group and developed technical joint training efforts with local regulatory associations. Ms. Messa chaired the Office of Regulatory Affairs/Center for Devices and Radiological Health (CDRH) Medical Device Field Committee, representing field activities and interests within CDRH. She participated in the development and implementation of regulations, guidance, policy, and compliance programs, including the Medical Device Quality System Regulation, Medical Device Mutual Recognition Agreement, Warning Letter Pilot, and Quality System Inspection Technique.

In their new roles, Mr. Handley and Ms. Messa will report directly to Mr. Geisenheimer, and Ms. Messa will also work closely with the Compliance Committee of the Company’s Board of Directors. Mr. Handley and Ms. Messa will be supported in their efforts by Reglera, a leading consulting organization specializing in quality and regulatory consulting.

About Spectranetics

Spectranetics manufactures and markets the only Excimer Laser System approved in the United States, Canada, Europe and Japan for use in minimally invasive interventional procedures within the cardiovascular system. More than 800 Spectranetics laser systems are used in hospitals worldwide.

The Company’s Vascular Intervention (VI) products include a range of peripheral and cardiac laser catheters for ablation of occluded arteries above and below the knee and within coronary arteries. The Company also markets aspiration catheters for the removal of thrombus and support catheters to facilitate crossing of coronary and peripheral arterial blockages.

The Lead Management (LM) product line includes excimer laser sheaths and cardiac lead management accessories for the removal of pacemaker and defibrillator cardiac leads.

For more information visit www.spectranetics.com.

Safe Harbor Statement

This news release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Such statements are based on current assumptions that involve risks and uncertainties that could cause actual outcomes and results to differ materially. These risks and uncertainties may include adverse results of the FDA and Immigration and Customs Enforcement investigation, adverse results of the SEC investigation or any securities litigation in which the Company or any of its officers or directors is a party, market acceptance of excimer laser atherectomy technology, increasing price and product competition, increased pressure on expense levels resulting from expanded sales, marketing, product development and clinical activities, uncertain success of the Company's strategic direction, dependence on new product development, intellectual property claims of third parties, availability of inventory from suppliers, the receipt of FDA approval to market new products or applications and the timeliness of any approvals, market acceptance of new products or applications, product defects, ability to manufacture sufficient volumes to fulfill customer demand, availability of vendor-sourced components at reasonable prices, unexpected delays or costs associated with the Company’s relocation and consolidation of its headquarters and manufacturing operations, and price volatility due to the initiation or cessation of coverage, or changes in ratings, by securities analysts. For a further list and description of such risks and uncertainties that could cause the actual results, performance or achievements of the Company to be materially different from any anticipated results, performance or achievements, please see the Company's previously filed SEC reports. Spectranetics disclaims any intention or obligation to update or revise any financial projections or forward-looking statements, whether as a result of new information, future events or otherwise.